Protocol Ledger

NCT05849727 · Phase II · TERMINATED

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Interventional Phase II clinical trial protocol NCT05849727 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-30 Enrollment: 195 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05849727
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)195 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05849727
Protocol FieldVerified Registry Value
NCT IdentifierNCT05849727
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment195 participants (ACTUAL)
Registered Start Date2023-08-30
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05849727
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI